EA201990553A1 - APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY - Google Patents

APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY

Info

Publication number
EA201990553A1
EA201990553A1 EA201990553A EA201990553A EA201990553A1 EA 201990553 A1 EA201990553 A1 EA 201990553A1 EA 201990553 A EA201990553 A EA 201990553A EA 201990553 A EA201990553 A EA 201990553A EA 201990553 A1 EA201990553 A1 EA 201990553A1
Authority
EA
Eurasian Patent Office
Prior art keywords
functional ability
patient
pridopidin
treatment
application
Prior art date
Application number
EA201990553A
Other languages
Russian (ru)
Inventor
Майкл Хейден
Спиридон Папапетрополос
Юха-Матти Савола
Эли Эял
Бет Боровски
Игорь Д. Грачёв
Original Assignee
Приления Терапьютикс Девелопмент Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Приления Терапьютикс Девелопмент Лтд. filed Critical Приления Терапьютикс Девелопмент Лтд.
Priority claimed from PCT/US2017/048461 external-priority patent/WO2018039477A1/en
Publication of EA201990553A1 publication Critical patent/EA201990553A1/en

Links

Abstract

В данном изобретении предлагается способ поддержания функциональной способности, улучшения функциональной способности или уменьшения ухудшения функциональной способности у пациента-человека, включающий периодическое пероральное введение пациенту фармацевтической композиции, содержащей придопидин, так, чтобы доза посуточно вводимого пациенту придопидина составляла 90-225 мг, чтобы таким образом поддержать функциональную способность, улучшить функциональную способность или уменьшить ухудшение функциональной способности у человека-пациента.The present invention provides a method for maintaining functional ability, improving functional ability, or reducing impairment of functional ability in a human patient, comprising periodically administering to the patient a pharmaceutical composition containing pridopidine so that the daily dose of pridopidine administered to the patient is 90-225 mg, so that maintain functional ability, improve functional ability or reduce impairment of functional ability in humans the patient.

EA201990553A 2016-11-02 2017-08-24 APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY EA201990553A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416685P 2016-11-02 2016-11-02
PCT/US2017/048461 WO2018039477A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating functional decline

Publications (1)

Publication Number Publication Date
EA201990553A1 true EA201990553A1 (en) 2019-08-30

Family

ID=67734917

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990553A EA201990553A1 (en) 2016-11-02 2017-08-24 APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY

Country Status (1)

Country Link
EA (1) EA201990553A1 (en)

Similar Documents

Publication Publication Date Title
MX2022003072A (en) Use of pridopidine for treating functional decline.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2020004023A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
MX368504B (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof.
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201890654A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
MX2022015629A (en) Use of vibegron to treat overactive bladder.
MX2016016400A (en) Stabilized oxymetazoline formulations and their uses.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
EA201990553A1 (en) APPLICATION OF PRIDOPIDIN FOR TREATMENT OF FUNCTIONAL ABILITY
MX2020001217A (en) Methods of treating symptoms of gastroparesis using velusetrag.
BR112018002433A2 (en) pharmaceutical composition for migraine treatment
MX2023004516A (en) Use of pridopidine and analogs for the treatment of anxiety and depression.
ZA202104321B (en) Aqueous paediatric retinol formulations
EA202190247A1 (en) APPLICATION OF RHC STIMULATORS FOR TREATMENT OF MITOCHONDRIAL DISEASES
EA201992816A1 (en) PHARMACEUTICAL COMPOSITION AND MEDICINAL FORM THAT INCLUDES (E) -4- (2- (AMINOMETHYL) -3-FLOROLLYLOXY) -N-THR-BUTYLBENZAMIDE, METHOD FOR THEIR PREPARATION AND APPLICATION, APPLICATION
SG10201700775YA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
BR112018017167A2 (en) cebranopadol titration